Business Context and Reporting Period
This Form 8-K is a current report filed by NantKwest, Inc. (not Immunitybio, Inc.) on August 2, 2019. The registrant is a Delaware corporation with its principal executive offices in San Diego, CA, and its common stock trades on the Nasdaq Global Select Market under the symbol "NK". The company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance amendments and does not contain financial performance data.
Material Changes
On August 2, 2019, the Board of Directors adopted amended and restated bylaws. The primary material changes include:
- Implementation of requirements under SB 826 mandating female representation on boards of directors.
- Establishment of a new Nominating and Corporate Governance Committee.
- Establishment of a new Related Party Transaction Committee.
Guidance, Outlook, and Management Commentary
Management stated the changes were made in the interest of maintaining good corporate governance practices. The filing does not provide financial guidance, outlook, or discuss specific risks, contingencies, or unusual items beyond the governance updates.
Committee Appointments
- Nominating and Corporate Governance Committee: Cheryl Cohen (Chair), Michael Blaszyk, Steve Gorlin.
- Related Party Transaction Committee: John Thomas (Chair), Cheryl Cohen, Frederick Driscoll, Michael Blaszyk.
Investor Verification Checklist
- Verify the complete text of the Amended and Restated Bylaws filed as Exhibit 3.1.
- Confirm the specific provisions of SB 826 and how the company plans to meet the female representation mandate.
- Review the company's most recent 10-K or 10-Q for actual financial metrics, as this 8-K contains none.